8. Huntington disease Clinical trials / Disease details
Clinical trials : 242 / Drugs : 205 - (DrugBank : 62) / Drug target genes : 85 - Drug target pathways : 159
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05475483 (ClinicalTrials.gov) | August 2, 2022 | 22/7/2022 | Efficacy and Safety on SOM3355 in Huntington's Disease Chorea | Phase IIb, Randomized, Double-blind, Placebo-controlled Study in Parallel Groups Assessing the Efficacy and Safety of Two Doses of SOM3355 in Patients Suffering From Huntington's Disease With Choreic Movements | Huntington Chorea | Drug: SOM3355 capsules;Drug: Placebo capsules | SOM Innovation Biotech SA | NULL | Recruiting | 21 Years | N/A | All | 129 | Phase 2 | France;Germany;Italy;Poland;Spain;Switzerland;United Kingdom |